Ultragenyx Pharmaceutical Inc. RARE
1,000 filings, 7 in the last 30 days
SEC filing indexWhat the 8-Ks said
2 events in the last 3 years: the officer, auditor, restatement, cyber, restructuring, listing, impairment and debt items. One line each, the filing's own words.
- Nov 3, 2026 RestructuringReported exit or disposal costs from a restructuring “Costs Associated with Exit or Disposal Activities. On November 3, 2026, the Company announced a restructuring plan to reduce expenses (the “Restructuring”). As part of the Restructuring, the Company is implementing a workforce reduction of approximately 20% of its employees (the “RIF”). The Company communicated the RIF on November 3, 2026 and expects the RIF to be substantially completed by the…” 8-K item 2.05 · all documents
- Feb 12, 2026 RestructuringReported exit or disposal costs from a restructuring “Costs Associated with Exit or Disposal Activities. On February 12, 2026, the Company began implementation of a strategic restructuring plan to reduce expenses (the “Restructuring”). As part of the Restructuring, the Company is implementing a 10% workforce reduction of approximately 130 employees across the Company (the “RIF”). The Company began notifying affected employees on February 12, 2026,…” 8-K item 2.05 · all documents
From the SEC filing index and the text of each 8-K. A line appears only when the 8-K names one of these items; for item 5.02 only a move of the CEO, CFO, COO or chief accounting officer. Older 8-Ks may have no text downloaded, so they show no quote.
Late filings, 8-K notices and going concern
None found in the last 2 years
-
Late filing notices (NT 10-K, NT 10-Q)No notice in the last 2 years.
-
8-K notices: listing, impairment, debt triggerNo item 3.01, 2.06 or 2.04 in the last 2 years.
-
Going-concern language in the 10-KNo statement of substantial doubt in the latest 10-K.
Facts to read in the filing, not a verdict: many companies with one of these carry on normally, and a company with neither can still have problems.
Every filing on one line
Each mark is a filing or an event in one; the bigger square is a 10-K. Hover for what it is, click to open it.
All 77 events
- Nov 4, 2026 10-Q Quarterly report (10-Q)period ended Sep 30, 2026
- Nov 3, 2026 8-K Acquisition or sale of assets completed, Quarterly results, Restructuring or exit costs8-K items 2.01, 2.02, 2.05
- Oct 19, 2026 8-K Other events8-K item 8.01
- Oct 14, 2026 8-K Material agreement signed8-K item 1.01
- Oct 7, 2026 8-K Material agreement signed8-K item 1.01
- Sep 17, 2026 8-K Other events8-K item 8.01
- Sep 15, 2026 Planned sale THEODORE HUIZENGA (Officer) gave notice of a planned sale of 1,283 shares worth about $17KForm 144, approximate sale date Sep 15, 2026, under a 10b5-1 plan adopted Jun 4, 2026
- Sep 2, 2026 8-K Other events8-K item 8.01
- Aug 19, 2026 8-K Other events8-K item 8.01
- Aug 11, 2026 8-K Other events8-K item 8.01
- Aug 5, 2026 Planned sale John Pinion (EVP, Chief Quality Officer and Translational Sciences) adopted a 10b5-1 trading planreported in the 10-Q, up to 19,936 shares, runs to May 18, 2027
- Aug 5, 2026 Planned sale Theodore Huizenga (Senior Vice President and Chief Accounting Officer) adopted a 10b5-1 trading planreported in the 10-Q, up to 4,726 shares, runs to Jan 31, 2027
- Aug 5, 2026 Planned sale Howard Horn (Executive Vice President, Chief Financial Officer, Corporate Strategy) adopted a 10b5-1 trading planreported in the 10-Q, up to 9,394 shares, runs to Jun 4, 2027
- Aug 5, 2026 10-Q Quarterly report (10-Q)period ended Jun 30, 2026
- Aug 4, 2026 8-K Quarterly results8-K item 2.02
- Aug 3, 2026 Planned sale HOWARD HORN (Officer) gave notice of a planned sale of 4,696 shares worth about $117KForm 144, approximate sale date Aug 3, 2026, under a 10b5-1 plan adopted Sep 2, 2025
- Jul 1, 2026 Planned sale HOWARD HORN (Officer) gave notice of a planned sale of 4,698 shares worth about $156KForm 144, approximate sale date Jul 1, 2026, under a 10b5-1 plan adopted Sep 2, 2025
- Jun 15, 2026 Planned sale CORAZON D. SANDERS (Director) gave notice of a planned sale of 2,000 shares worth about $50KForm 144, approximate sale date Jun 15, 2026
- Jun 15, 2026 Planned sale KARAH PARSCHAUER (Officer) gave notice of a planned sale of 3,799 shares worth about $93KForm 144, approximate sale date Jun 15, 2026, under a 10b5-1 plan adopted Mar 16, 2026
- Jun 1, 2026 Planned sale HOWARD HORN (Officer) gave notice of a planned sale of 4,653 shares worth about $111KForm 144, approximate sale date Jun 1, 2026, under a 10b5-1 plan adopted Sep 2, 2025
- May 18, 2026 Planned sale SHEHNAAZ SULIMAN (Director) gave notice of a planned sale of 5,740 shares worth about $144KForm 144, approximate sale date May 18, 2026, under a 10b5-1 plan adopted Sep 15, 2025
- May 18, 2026 8-K Director or officer change, Shareholder vote results8-K items 5.02, 5.07
- May 6, 2026 Planned sale Karah Parschauer (Executive Vice President, Chief Legal Officer and Corporate Affairs) adopted a 10b5-1 trading planreported in the 10-Q, up to 54,937 shares, runs to Mar 13, 2027
- May 6, 2026 Planned sale Matthew Fust (Director) adopted a 10b5-1 trading planreported in the 10-Q, up to 3,750 shares, runs to Mar 12, 2027
- May 6, 2026 10-Q Quarterly report (10-Q)period ended Mar 31, 2026
- May 5, 2026 8-K Quarterly results8-K item 2.02
- May 1, 2026 Planned sale HOWARD HORN (Officer) gave notice of a planned sale of 4,683 shares worth about $117KForm 144, approximate sale date May 1, 2026, under a 10b5-1 plan adopted Sep 2, 2025
- Apr 2, 2026 8-K Other events8-K item 8.01
- Apr 1, 2026 Planned sale HOWARD HORN (Officer) gave notice of a planned sale of 4,683 shares worth about $98KForm 144, approximate sale date Apr 1, 2026, under a 10b5-1 plan adopted Sep 2, 2025
- Mar 30, 2026 8-K Other events8-K item 8.01
- Mar 12, 2026 8-K Other events8-K item 8.01
- Mar 10, 2026 Planned sale KARAH PARSCHAUER (Officer) gave notice of a planned sale of 3,508 shares worth about $80KForm 144, approximate sale date Mar 10, 2026
- Mar 6, 2026 Planned sale KARAH PARSCHAUER (Officer) gave notice of a planned sale of 6,018 shares worth about $129KForm 144, approximate sale date Mar 6, 2026
- Mar 3, 2026 Planned sale HOWARD HORN (Officer) gave notice of a planned sale of 1,635 shares worth about $37KForm 144, approximate sale date Mar 3, 2026, under a 10b5-1 plan adopted Sep 2, 2025
- Mar 2, 2026 Planned sale HOWARD HORN (Officer) gave notice of a planned sale of 3,119 shares worth about $70KForm 144, approximate sale date Mar 2, 2026, under a 10b5-1 plan adopted Sep 2, 2025
- Feb 23, 2026 8-K Other events8-K item 8.01
- Feb 18, 2026 10-K Annual report (10-K)period ended Dec 31, 2025
- Feb 12, 2026 8-K Quarterly results, Restructuring or exit costs8-K items 2.02, 2.05
- Feb 3, 2026 8-K Other events8-K item 8.01
- Feb 2, 2026 Planned sale HOWARD HORN (Officer) gave notice of a planned sale of 3,061 shares worth about $72KForm 144, approximate sale date Feb 2, 2026, under a 10b5-1 plan adopted Sep 2, 2025
- Jan 30, 2026 8-K Other events8-K item 8.01
- Jan 12, 2026 8-K Quarterly results8-K item 2.02
- Jan 2, 2026 Planned sale HOWARD HORN (Officer) gave notice of a planned sale of 3,150 shares worth about $72KForm 144, approximate sale date Jan 2, 2026, under a 10b5-1 plan adopted Sep 2, 2025
- Dec 30, 2025 8-K Other events8-K item 8.01
- Dec 29, 2025 8-K Other events8-K item 8.01
- Dec 10, 2025 Planned sale HOWARD HORN (Officer) gave notice of a planned sale of 3,081 shares worth about $112KForm 144, approximate sale date Dec 10, 2025, under a 10b5-1 plan adopted Sep 2, 2025
- Nov 5, 2025 Planned sale Shehnaaz Suliman (Board Member) adopted a 10b5-1 trading planreported in the 10-Q, up to 26,427 shares, runs to Sep 15, 2026
- Nov 5, 2025 Planned sale Howard Horn (Chief Financial Officer and EVP, Corporate Strategy) adopted a 10b5-1 trading planreported in the 10-Q, up to 57,482 shares, runs to Sep 2, 2026
- Nov 5, 2025 Planned sale Eric Crombez (Chief Medical Officer) adopted a 10b5-1 trading planreported in the 10-Q, up to 45,238 shares, runs to Sep 5, 2026
- Nov 5, 2025 10-Q Quarterly report (10-Q)period ended Sep 30, 2025
- Nov 4, 2025 8-K Material agreement signed, Quarterly results8-K items 1.01, 2.02
- Oct 30, 2025 8-K Other events8-K item 8.01
- Sep 8, 2025 8-K Other events8-K item 8.01
- Aug 18, 2025 8-K Other events8-K item 8.01
- Aug 6, 2025 Planned sale Shehnaaz Suliman (Board Member) adopted a 10b5-1 trading planreported in the 10-Q, up to 27,110 shares, runs to May 15, 2026
- Aug 6, 2025 Planned sale John Pinion (Translational Research and Chief Quality Officer) adopted a 10b5-1 trading planreported in the 10-Q, up to 30,736 shares, runs to May 8, 2026
- Aug 6, 2025 10-Q Quarterly report (10-Q)period ended Jun 30, 2025
- Aug 5, 2025 8-K Quarterly results8-K item 2.02
- Jul 31, 2025 8-K Other events8-K item 8.01
- Jul 11, 2025 8-K Other events8-K item 8.01
- Jul 9, 2025 8-K Other events8-K item 8.01
- Jun 27, 2025 8-K Other events8-K item 8.01
- May 19, 2025 8-K Director or officer change, Shareholder vote results8-K items 5.02, 5.07
- May 7, 2025 Planned sale Karah Parschauer (Chief Legal Officer and Corporate Affairs) adopted a 10b5-1 trading planreported in the 10-Q, up to 54,601 shares, runs to Mar 3, 2026
- May 7, 2025 Planned sale Emil D. Kakkis (President and CEO, Director) adopted a 10b5-1 trading planreported in the 10-Q, up to 100,000 shares, runs to Mar 17, 2026
- May 7, 2025 10-Q Quarterly report (10-Q)period ended Mar 31, 2025
- May 6, 2025 8-K Quarterly results8-K item 2.02
- Feb 19, 2025 Planned sale Shehnaaz Suliman (Board Member) adopted a 10b5-1 trading planreported in the 10-K, up to 27,110 shares
- Feb 19, 2025 Planned sale Corsee Sanders (Board Member) adopted a 10b5-1 trading planreported in the 10-K, up to 2,405 shares
- Feb 19, 2025 Planned sale Matthew Fust (Board Member) adopted a 10b5-1 trading planreported in the 10-K, up to 15,000 shares
- Feb 19, 2025 Planned sale Eric Crombez (Chief Medical Officer) adopted a 10b5-1 trading planreported in the 10-K, up to 64,235 shares
- Feb 19, 2025 Planned sale Howard Horn (Chief Financial Officer) adopted a 10b5-1 trading planreported in the 10-K, up to 17,477 shares
- Feb 19, 2025 10-K Annual report (10-K)period ended Dec 31, 2024
- Feb 13, 2025 8-K Quarterly results8-K item 2.02
- Jan 13, 2025 8-K Quarterly results8-K item 2.02
- Dec 19, 2024 8-K Other events8-K item 8.01
- Dec 19, 2024 8-K Other events8-K item 8.01
From the SEC filing index. Insider purchases go back 180 days (the Form 4s downloaded).
Every filing
Newest first, by kind · each form links to sec.gov
| Filed | Form | What it is |
|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| Nov 4, 2026 | 10-Q | Quarterly report |
| Nov 3, 2026 | 8-K | Acquisition or sale of assets completed, Quarterly results, Restructuring or exit costs |
| Oct 30, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| Oct 20, 2026 | SCHEDULE 13G | 5%+ owner (passive) |
| Oct 19, 2026 | 4 | Insider trade |
| Oct 19, 2026 | 8-K | Other events |
| Oct 14, 2026 | 8-K | Material agreement signed |
| Oct 7, 2026 | 8-K | Material agreement signed |
| Sep 17, 2026 | 8-K | Other events |
| Sep 15, 2026 | 144 | Notice of planned insider sale |
| Sep 15, 2026 | 4 | Insider trade |
| Sep 8, 2026 | 4 | Insider trade |
| Sep 2, 2026 | 8-K | Other events |
| Aug 19, 2026 | 8-K | Other events |
| Aug 14, 2026 | SCHEDULE 13G | 5%+ owner (passive) |
| Aug 13, 2026 | SCHEDULE 13G | 5%+ owner (passive) |
| Aug 11, 2026 | 8-K | Other events |
| Aug 5, 2026 | 10-Q | Quarterly report |
| Aug 4, 2026 | 8-K | Quarterly results |
| Aug 4, 2026 | 4 | Insider trade |
| Aug 4, 2026 | 4 | Insider trade |
| Aug 3, 2026 | 144 | Notice of planned insider sale |
| Jul 31, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| Jul 31, 2026 | SCHEDULE 13G | 5%+ owner (passive) |
| Jul 30, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| Jul 6, 2026 | 4 | Insider trade |
| Jul 1, 2026 | 144 | Notice of planned insider sale |
| Jun 15, 2026 | 144 | Notice of planned insider sale |
| Jun 15, 2026 | 144 | Notice of planned insider sale |
| Jun 15, 2026 | 4 | Insider trade |
| Jun 15, 2026 | 4 | Insider trade |
| Jun 12, 2026 | S-8 | Shares registered for employee plans |
| Jun 1, 2026 | 144 | Notice of planned insider sale |
| Jun 1, 2026 | 4 | Insider trade |
| May 18, 2026 | 144 | Notice of planned insider sale |
| May 18, 2026 | 4 | Insider trade |
| May 18, 2026 | 4 | Insider trade |
| May 18, 2026 | 4 | Insider trade |
| May 18, 2026 | 4 | Insider trade |
| May 18, 2026 | 4 | Insider trade |
| May 18, 2026 | 4 | Insider trade |
| May 18, 2026 | 4 | Insider trade |
| May 18, 2026 | 8-K | Director or officer change, Shareholder vote results |
| May 6, 2026 | 4 | Insider trade |
| May 6, 2026 | 10-Q | Quarterly report |
| May 5, 2026 | 8-K | Quarterly results |
| May 4, 2026 | 4 | Insider trade |
| May 1, 2026 | 144 | Notice of planned insider sale |
| Apr 30, 2026 | DEFA14A | Extra proxy material |
| Apr 29, 2026 | SCHEDULE 13G | 5%+ owner (passive) |
| Apr 24, 2026 | 4 | Insider trade |
| Apr 20, 2026 | 4 | Insider trade |
| Apr 20, 2026 | 4 | Insider trade |
| Apr 20, 2026 | 4 | Insider trade |
| Apr 20, 2026 | 4 | Insider trade |
| Apr 20, 2026 | 4 | Insider trade |
| Apr 20, 2026 | 4 | Insider trade |
| Apr 20, 2026 | 4 | Insider trade |
| Apr 2, 2026 | 4 | Insider trade |
| Apr 2, 2026 | 8-K | Other events |
| Apr 1, 2026 | 144 | Notice of planned insider sale |
| Mar 30, 2026 | 8-K | Other events |
| Mar 27, 2026 | ARS | Annual report to shareholders |
| Mar 27, 2026 | DEFA14A | Extra proxy material |
| Mar 27, 2026 | DEF 14A | Proxy statement |
| Mar 27, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| Mar 12, 2026 | 8-K | Other events |
| Mar 10, 2026 | 144 | Notice of planned insider sale |
| Mar 10, 2026 | 4 | Insider trade |
| Mar 6, 2026 | 144 | Notice of planned insider sale |
| Mar 3, 2026 | 144 | Notice of planned insider sale |
| Mar 3, 2026 | 4 | Insider trade |
| Mar 3, 2026 | 4 | Insider trade |
| Mar 3, 2026 | 4 | Insider trade |
| Mar 3, 2026 | 4 | Insider trade |
| Mar 3, 2026 | 4 | Insider trade |
| Mar 3, 2026 | 4 | Insider trade |
| Mar 3, 2026 | 4 | Insider trade |
| Mar 3, 2026 | 4 | Insider trade |
| Mar 2, 2026 | 144 | Notice of planned insider sale |
| Feb 23, 2026 | 8-K | Other events |
| Feb 18, 2026 | 10-K | Annual report |
| Feb 12, 2026 | 8-K | Quarterly results, Restructuring or exit costs |
| Feb 5, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| Feb 3, 2026 | 4 | Insider trade |
| Feb 3, 2026 | 8-K | Other events |
| Feb 2, 2026 | 144 | Notice of planned insider sale |
| Jan 30, 2026 | 8-K | Other events |
| Jan 12, 2026 | 8-K | Quarterly results |
| Jan 5, 2026 | 4 | Insider trade |
| Jan 2, 2026 | 144 | Notice of planned insider sale |
| Dec 30, 2025 | 8-K | Other events |
| Dec 30, 2025 | 4 | Insider trade |
| Dec 29, 2025 | 8-K | Other events |
| Dec 11, 2025 | 4 | Insider trade |
| Dec 10, 2025 | 144 | Notice of planned insider sale |
| Nov 5, 2025 | 10-Q | Quarterly report |
| Nov 5, 2025 | SCHEDULE 13G | 5%+ owner (passive) |
| Nov 4, 2025 | 8-K | Material agreement signed, Quarterly results |
Show the other 75 filings on this page
Press releases with quarterly results are attached to the 8-Ks marked "Quarterly results"; read them on Earnings releases.
Sources
SEC's filing index (data.sec.gov submissions). Each form links to the document on sec.gov.
Also
Earnings releases: the text of each quarter's results release. Statements by period: the income statement, balance sheet or cash flow of the last filings side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RARE/export.csv") into a cell.